In 1989, rhEPO was approved by the Food and Drug Administration of the United States of America for clinical treatment of anemia associated with chronic renal failure due to insufficient EPO production and showed improvement in the life quality of patients (Wright et al., 2015; Suresh et al., 2019). The gene discussed is EPO; the disease is anemia.